Amgen completes acquisition of KAI Pharmaceuticals

Free news subscription available

RSS feed: news [?]

21.05.2013: China's crude oil imports up 3.7 percent; BP commissions new diesel, hydrogen units at Cherry Point Refinery in Washington; Bridgestone Americas breaking ground on new Biorubber Process Research Center; Tessenderlo Group sells its chloro-aromatics business in Italy; Canada's Enerkem to develop waste-to-biofuels catalytic processes; Sunoco Logistics acquires Marcus Hook refinery; BASF plans butanediol production from renewable feedstock using the patented technology process of Genomatica; Evonik Industries selects OPX Biotechnologies for joint development of bio-based chemicals; TOYO awarded FEED for polyethylene plant in USA for Sasol North America
20.05.2013: Solazyme and AkzoNobel enter agreement spanning surfactants and coatings markets; Sulzer Pumps supplies to new floating production storage and offloading (FPSO) vessel in Brazil; Merck and Pfizer enter worldwide collaboration agreement to develop and commercialize Еrtugliflozin for the treatment of type 2 diabetes; ERT granted a licence to Falanx for the manufacture and sale of products made using the PIM process; Grupa Azoty S.A. and Air Products continue their investment process; Versalis and Genomatica launch JV for bio-based butadiene production process; Teva and Alexza announce Teva’s license to market ADASUVE® in the U.S.; Valvoline Cummins Limited opens new India manufacturing and packaging facility for automotive lubricants
17.05.2013: Wacker Chemie starts up new production plant for VAE dispersions in China; Ico Polymers buoys marine material range; Sumy Frunze NPO to supply of nitrous gases cooler for JSC «Azot»

Free news subscription available

Home

News

Conference and Exhibition

Schematic maps of industry

Preliminary editorial plan for 2013

Issues archive

2013
№01	№02	№03
№04
2012
№01	№02	№03
№04	№05	№06
№07	№08	№09
№10	№11	№12
2011
№01	№02	№03
№04	№05	№06
№07	№08	№09
№10	№11	№12
2010
№01	№02	№03
№04	№05	№06
№07	№08	№09
№10	№11	№12
2009
№01	№02	№03
№04	№05	№06
№07	№08	№09
№10	№11	№12
2008
№01	№02	№03
№04	№05	№06
№07	№08	№09
№10	№11	№12
2007
№01	№02	№03
№04	№05	№06
№07	№08	№09
№10	№11	№12

Home » News » Amgen completes acquisition of KAI Pharmaceuticals

17.07.2012	Amgen completes acquisition of KAI Pharmaceuticals

Amgen (NASDAQ: AMGN) announced the completion of the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco. The acquisition was initially announced April 10, 2012 and includes KAI's lead product candidate KAI-4169, which is a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. KAI has previously reported compelling Phase 2a clinical results for KAI-4169 in this indication. KAI-4169 is administered intravenously at the same time the patient is undergoing dialysis.

Our Partners

Conference and Exhibition, held under an informational support of the magazine "Eurasian chemical market"

The 8th Russia & CIS Bottom of the Barrel Technology Conference & Exhibition

﻿Amgen completes acquisition of KAI Pharmaceuticals

Amgen completes acquisition of KAI Pharmaceuticals